Chloroquine is grossly under dosed in young children with malaria: Implications for drug resistance

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ursing, Johan ^a,b   Eksborg, Staffan ^c   Rombo, Lars ^b,d   Bergqvist, Yngve ^e   Blessborn, Daniel ^f,g   Rodrigues, Amabelia ^a   Kofoed, Poul Erik ^a,h  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e DALARNA UNIVERSITY   (Sweden)

^f MAHIDOL UNIVERSITY   (Thailand)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h KOLDING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE;

ADOLESCENT; AGE; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; CHILD SAFETY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; PRESCHOOL CHILD; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHOOL CHILD;

ADOLESCENT; AFRICA; AGE FACTORS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

EID: 84899865639     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086801     Document Type: Article

References (44)

1. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, et al. (2006) Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 1959-1966. (Pubitemid 44708015)
2. Ndiaye M, Faye B, Tine R, Ndiaye JL, Lo A, et al. (2012) Assessment of the Molecular Marker of Plasmodium falciparum Chloroquine Resistance (Pfcrt) in Senegal after Several Years of Chloroquine Withdrawal. Am J Trop Med Hyg 87: 640-645.
3. Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, et al. (2012) A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS One 7: e42284.
4. Mita T, Tanabe K, Kita K (2009) Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int 58: 201-209.
5. Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, et al. (2007) Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J Infect Dis 196: 1613-1619. (Pubitemid 351411958)
6. Kofoed PE, Lopez F, Johansson P, Sandstrom A, Hedegaard K, et al. (2002) Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg 67: 28-31. (Pubitemid 35034316)
7. Kofoed PE, Ursing J, Poulsen A, Rodrigues A, Bergquist Y, et al. (2007) Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans R Soc Trop Med Hyg 101: 231-238. (Pubitemid 46043055)
8. Ursing J, Kofoed PE, Rodrigues A, Bergqvist Y, Rombo L (2009) Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau. Antimicrob Agents Chemother 53: 180-185.
9. Ursing J, Kofoed PE, Rodrigues A, Blessborn D, Thoft-Nielsen R, et al. (2011) Similar efficacy and tolerability of double-dose chloroquine and artemetherlumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis 203: 109-116.
10. Ursing J, Kofoed PE, Rodrigues A, Rombo L (2009) No seasonal accumulation of resistant P. falciparum when high-dose chloroquine is used. PLoS One 4: e6866.
11. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP (2007) Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am J Trop Med Hyg 76: 844-848. (Pubitemid 351627666)
12. Scragg JN, Powell SJ (1968) Emetine hydrochloride and dehydroemetine combined with chloroquine in the treatment of children with amoebic liver abscess. Arch Dis Child 43: 121-123.
13. Canete R, Rivas DE, Escobedo AA, Gonzalez ME, Almirall P, et al. (2010) A randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children. West Indian Med J 59: 607-611.
14. Loeb F, Clark WM, Coatney GR, Coggeshall LT, Dieuaide FR, et al. (1946) Activity of a new antimalarial agent, chloroquine (SN 7618). J Am Med Assoc 130: 1069-1070.
15. Most H, London IM, Kane CA, Lavietes PH, Schroeder EF, et al. (1946) Chloroquine for treatment of acute attacks of vivax malaria. J Am Med Assoc 131: 963-967.
16. Eksborg S, Pal N, Kalin M, Palm C, Soderhall S (2002) Pharmacokinetics of acyclovir in immunocompromized children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 38: 240-246. (Pubitemid 34258415)
17. Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, et al. (2001) Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 85: 23-28. (Pubitemid 32695711)
18. World Health Organization (2010) Guidelines for the treatment of malaria (Second edition).
19. Adjepon-Yamoah KK, Ofori-Adjei D, Woolhouse NM, Lindstrom B (1986) Whole-blood single-dose kinetics of chloroquine and desethylchloroquine in Africans. Ther Drug Monit 8: 195-199. (Pubitemid 16084177)
20. McChesney EW, Banks WF, Jr., Fabian RJ (1967) Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat. Toxicol Appl Pharmacol 10: 501-513.
21. Krishna S, White NJ (1996) Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 30: 263-299.
22. Looareesuwan S, White NJ, Chanthavanich P, Edwards G, Nicholl DD, et al. (1986) Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol 22: 31-36. (Pubitemid 17177201)
23. Verdier F, Le Bras J, Clavier F, Hatin I (1984) Blood levels and in vitro activity of desethylchloroquine against Plasmodium falciparum. Lancet 1: 1186-1187. (Pubitemid 14108733)
24. Mack RB (1984) 4-aminoquinolines can be dangerous to your health: chloroquine (Aralen) intoxication. N C Med J 45: 245-246.
25. Smith ER, Klein-Schwartz W (2005) Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 28: 437-443. (Pubitemid 40523693)
26. Abiose AK, Grossmann M, Tangphao O, Hoffman BB, Blaschke TF (1997) Chloroquine-induced venodilation in human hand veins. Clin Pharmacol Ther 61: 677-683. (Pubitemid 27279930)
27. Aviado DM, Sadavongvivad C, Cambar P (1970) Cardiopulmonary effects of antimalarial drugs. 1. 4-Aminoquinolines: chloroquine quinetholate. Toxicol Appl Pharmacol 17: 107-117.
28. Tona L, Ng YC, Akera T, Brody TM (1990) Depressant effects of chloroquine on the isolated guinea-pig heart. Eur J Pharmacol 178: 293-301. (Pubitemid 20126668)
29. Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, et al. (2007) Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2: e6.
30. Boyd E (1935) The growth of the surface area of the human body. Minneapolis: Institute of Child Welfare.
31. Lindegårdh N, Forslund M, Green MD, Kaneko A, Bergqvist Y (2002) Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia: 5-12. (Pubitemid 34095147)
32. Obua C, Hellgren U, Ntale M, Gustafsson LL, Ogwal-Okeng JW, et al. (2008) Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen. Br J Clin Pharmacol 65: 493-501. (Pubitemid 351365129)
33. Moore BR, Page-Sharp M, Stoney JR, Ilett KF, Jago JD, et al. (2011) Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother 55: 3899-3907.
34. Lee SJ, McGready R, Fernandez C, Stepniewska K, Paw MK, et al. (2008) Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. Eur J Clin Pharmacol 64: 987-992.
35. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, et al. (1997) Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621-626. (Pubitemid 27318583)
36. Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B (1984) The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects. Eur J Clin Pharmacol 26: 521-530. (Pubitemid 14149135)
37. Kim KA, Park JY, Lee JS, Lim S (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26: 631-637.
38. Walker O, Dawodu AH, Adeyokunnu AA, Salako LA, Alvan G (1983) Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br J Clin Pharmacol 16: 701-705. (Pubitemid 14208210)
39. Ursing J, Schmidt BA, Lebbad M, Kofoed PE, Dias F, et al. (2007) Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage? Infect Genet Evol 7: 555-561. (Pubitemid 47342374)
40. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, Hellstrom L, Jansson F (1979) Chloroquine serum concentration and side effects: evidence for dosedependent kinetics. Clin Pharmacol Ther 25: 345-350. (Pubitemid 9164951)
41. White NJ (2007) Cardiotoxicity of antimalarial drugs. The Lancet infectious diseases 7: 549-558.
42. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M, et al. (2004) Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells. Eur J Pharmacol 484: 41-48. (Pubitemid 38068532)
43. Alkmim Teixeira R, Borba EF, Pedrosa A, Nishioka S, Viana VS, et al. (2013) Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus. Europace.
44. Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA (2013) Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med 5: 205ra135.